Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2018-08-17

FDA Approved: RADICAVA — Supplemental Application (Shionogi Inc.)

View source ↗

Summary

The FDA approved a supplemental NDA for RADICAVA (edaravone) from Shionogi Inc., updating its regulatory status after the supplemental application was reviewed.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Radicava (edaravone)

Snippet

SUPPL AP for RADICAVA (EDARAVONE)